Skip to main navigation

About

Our Story Executive Team Board of Directors

Technology and Platforms

Our Approach FasTCAR TruUCAR Manufacturing

Pipeline

Investors

Overview News & Events Financial Information Stock Information Corporate Governance IR Resources Contact Us

News Releases

Overview
News & Events
Financial Information
Stock Information
Corporate Governance
IR Resources
Contact Us

News & Events menu

News Releases
Events & Presentations
Publications

Year

Gracell Biotechnologies to Report Fourth Quarter and Fiscal 2020 Financial Results on Tuesday, March 9, 2021

SUZHOU and SHANGHAI, China , Feb. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it plans to release

Feb 23, 2021

Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL

SUZHOU and SHANGHAI, China , Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the

Jan 19, 2021

Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products

SUZHOU, China , Jan. 15, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted the Medical Products

Jan 15, 2021

China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL

SUZHOU and SHANGHAI, China , Jan. 13, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted approval for

Jan 13, 2021

Gracell Biotechnologies Announces Pricing of Initial Public Offering

SUZHOU and SHANGHAI, China , Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical

Jan 08, 2021

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 25 of 25

Shareholder Tools

Contact Us
Email Alerts
FAQs
RSS Feeds

Footer Links

Terms & Conditions
Privacy Policy
Contact Us
Careers